A counterfeit of the Harvoni drug, from the Gilead Sciences Farmacêutica do Brasil company, circulates in the country. See how to distinguish the original version of the product.
US FDA granted expanded approval for Mavyret that will allow patients to be treated for the hepatitis C virus in eight weeks.
More states are turning to alternative payment models for prescription drugs covered under Medicaid, as they seek to balance increasing costs with public health goals.
AbbVie is one of several companies to market the new class of hepatitis C (HCV) treatments known as Maviret (glecaprevir/pibrentasvir), which can cure patients of the serious blood infection. Maviret is in contention with rival treatments such as Gilead’s Sovaldi, Harvoni and Epclusa, to name a few.
Monday was a good-news-bad-news day for Gilead Sciences at the U.S. Supreme Court, with the justices handing down multiple decisions about which appeals they would take up as they headed back to work after the holiday break.
AbbVie`s latest hep C push highlights Mavyret`s time-to-cure advantage
Takeda is about to buy its way to a number 1 spot in the top tier of drugmakers fielding the most expensive drugs on the planet.
Express Scripts said Wednesday it's rolling out a new formulary aimed at giving will employers and health plans a way to cover lower priced products and reduce reliance on rebates for brand-name medicines.
Merck & Co. nabbed $200 million in damages after a hepatitis C patent fight with Gilead Sciences but quickly lost the whole shebang thanks to accusations of misconduct and fabricated testimony. And turns out, Merck doesn't want to let that cash go so easily.
At first glance, it seems like a logical idea: pharma companies teaching doctors' staff how to handle patients using their drugs and helping staffers with reimbursement questions. But a slew of companies are discovering that it's not so simple.